# Study Evaluating the Safety and Tolerability of Single Ascending Dose (SAD) SLV-351 in Healthy Subjects

> **NCT00581191** · PHASE1 · TERMINATED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 72 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** SLV-351

## Key facts

- **NCT ID:** NCT00581191
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2009-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00581191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00581191, "Study Evaluating the Safety and Tolerability of Single Ascending Dose (SAD) SLV-351 in Healthy Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00581191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*